The Federal Circuit heard arguments July 20, 2012 in the long-running dispute between The Association for Molecular Pathology and Myriad Genetics, Inc. (Myriad), which the Supreme Court returned to the Federal Circuit for reconsideration in view of the Supreme Court’s recent decision in Mayo Collaborative Services v. Prometheus Laboratories, Inc. In Prometheus, the Supreme Court held certain claims to methods of determining a dosage of a drug were not patent eligible subject matter, characterizing the claims as not significantly more than a law of nature and as too broadly preemptive of the natural law to be patent-eligible.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.